Helvaci, SezerSahinoglu-Keskek, NedimeKiziloglu, MustafaOksuz, HuseyinCevher, Selim2024-09-182024-09-1820152325-81602325-8179https://doi.org/10.3928/23258160-20150422-11https://hdl.handle.net/20.500.12483/13746BACKGROUND AND OBJECTIVE: The aim of the study was to evaluate vitreous incarceration at the injection site using ultrasound biomicroscopy (UBM) after intravitreal injection of ranibizumab. PATIENTS AND METHODS: The study included 39 eyes of 34 patients who underwent intravitreal injection of 0.05 mL of ranibizumab. UBM (HiScan; Optikon, Rome, Italy) with a 50 MHz probe was performed 1 day after surgery to determine the existence of vitreous incarceration at the injection site. RESULTS: The mean patient age was 59.7 (+/- 10.1) years, and 58.9% were female. Vitreous incarceration into the pars plana site was detected in six eyes (15.3%) the day after intravitreal injection. CONCLUSION: Vitreous incarceration at the injection site after intravitreal injection is thought to lead to a higher risk for complications such as infection, retinal breaks, retinal detachment, vitreous hemorrhage, and fibrovascular proliferation at the injection site. To understand the clinical importance of vitreous incarceration, further long-term prospective studies are necessary.eninfo:eu-repo/semantics/closedAccessPars-Plana VitrectomyIntraocular-Pressure ChangesIntravitreal Triamcinolone AcetonideSclerotomy Sites25-Gauge VitrectomyMacular DegenerationHemorrhageBevacizumabLucentisRetinaArticle46447147410.3928/23258160-20150422-11259327252-s2.0-84929406102Q3WOS:000359292300011Q3